Trial
NCT04149821
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
TG Therapeutics, Inc.
Condition
Chronic Lymphocytic Leukemia
Intervention
Umbralisib
Why stopped
Terminated due to low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-15